GlassScriptPhysician profile
Meg Schulte
NPI 1518427640
$4,837.90
in general payments reported to CMS, 2019-2025
25 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $289 · 2023: $854 · 2024: $1,246 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.61 | 2021-2025 | |
| Alkermes, INC. | $575.64 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $503.89 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $499.42 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $274.22 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $264.66 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $247.53 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $223.54 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $205.13 | 2024 | Spravato |
| Noven Therapeutics, LLC | $180.08 | 2024-2025 | Xelstrym, Secuado |
| Corium, LLC | $172.28 | 2024-2025 | Azstarys |
| Almatica Pharma LLC | $135.51 | 2023 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $124.97 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $116.19 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $108.30 | 2023-2025 | Quviviq, Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $107.50 | 2024-2025 | Raldesy, Equetro, Equetro |
| Jazz Pharmaceuticals INC. | $96.09 | 2023-2025 | |
| Neos Therapeutics, LP | $93.94 | 2023-2025 | Adzenys Xr-Odt, Exxua |
| Collegium Pharmaceutical, INC. | $81.42 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $46.50 | 2021-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $43.91 | 2025 | Uzedy |
| Avadel Cns Pharmaceuticals, LLC | $33.94 | 2025 | Lumryz |
| Orexo US, INC. | $31.35 | 2021-2023 | Zubsolv |
| Sage Therapeutics, LLC | $26.60 | 2025 | Zurzuvae |
| Novo Nordisk INC | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meg Schulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.